Bluejay Diagnostics, Inc. (BJDX)
NASDAQ: BJDX · Real-Time Price · USD
3.520
+0.020 (0.57%)
At close: Nov 22, 2024, 4:00 PM
3.680
+0.160 (4.55%)
After-hours: Nov 22, 2024, 7:16 PM EST
Bluejay Diagnostics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
1.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 249.04K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LogicMark | 10.08M |
| Tenon Medical | 3.32M |
| Elevai Labs | 2.45M |
| SciSparc | 1.75M |
| Catheter Precision | 399.00K |
| Cyclacel Pharmaceuticals | 74.00K |
BJDX News
- 9 days ago - Bluejay Diagnostics Announces Reverse Stock Split - GlobeNewsWire
- 5 months ago - Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering - GlobeNewsWire
- 5 months ago - SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients - GlobeNewsWire
- 11 months ago - Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering - GlobeNewsWire
- 11 months ago - Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering - GlobeNewsWire
- 11 months ago - Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study) - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - GlobeNewsWire